CLOs on the Move

Wayne Memorial Hospital

www.waynehealth.org

 
Wayne Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Wayne Memorial Hospital is based in Goldsboro, NC. You can find more information on Wayne Memorial Hospital at www.waynehealth.org
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Feinstein Kean Healthcare

Feinstein Kean Healthcare is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Cambridge, MA. To find more information about Feinstein Kean Healthcare, please visit www.fkhealth.com

Nu Image Medical

Nu Image Medical specializes in Weight Loss, Hormone Replacement, Sexual Enhancement and General Wellness. Our futuristic methods offer a new and updated approach to achieving optimum health and wellness not only through local brick-and-mortar establishments, but also online virtually through our telemedicine platform. Nu Image Medical has been proving patient services nationally since 2004, establishing itself as not on a leader in Regenerative Medicine, but also in the Telehealth industry. Nu Image Medical sets the standard for patients looking to receive quality expert medical care without boundaries.

World Class Health and Fitness

World Class Health & Fitness is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ISS Solutions

ISS Solutions is a Langhorne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.